Evista vs generic: are they the same? — for Mexico
Evista is the originator brand for the active ingredient Raloxifene. Once the original patent expired, authorised generic versions of the same active ingredient became available. For most users at 60mg, the practical question is: is the generic just as good, and what really differs?
Mexico context
Authorised generics of Raloxifene are typically dispensed in Mexico alongside or instead of branded Evista. Major chains (Farmacias del Ahorro, Farmacias Similares, Benavides) and independent farmacias dispense across Mexico. Many chain pharmacies offer adjacent low-cost consultations. The pharmacist applies local equivalence rules at the point of dispensing; the brand vs generic price gap in MXN is usually the most decisive economic factor for ongoing use.
- Regulator
- COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)
- Currency
- MXN
What is the same
Authorised generics of Raloxifene contain the same active substance at the same 60mg strength as Evista, with regulator-required bioequivalence to the originator. Clinical effect is, on average, the same. According to the prescribing information, generics meet the same regulatory standard and can substitute for the brand in most patients.
What can differ
Differences include manufacturer, country of production, excipients, tablet appearance, packaging and price. A small minority of patients react to a specific excipient that varies between manufacturers. Price is usually significantly lower for generics — often the most decisive practical difference for chronic use.
Frequently asked questions
Is generic Raloxifene as effective as Evista? ▾
For most users at 60mg, yes — authorised generics of Raloxifene are required to demonstrate bioequivalence to Evista and produce the same clinical effect on average. Some users notice no difference; a few report subjective differences that are usually due to excipients or expectation.
Why does Evista cost more than the generic? ▾
The price difference reflects the originator's development costs, brand recognition and marketing, plus the larger volume and competition among generic manufacturers. The active ingredient Raloxifene itself is identical between brand and authorised generic at 60mg.
Evista vs generic: are they the same? in other countries
- the United StatesFDA (Food and Drug Administration)
- the United KingdomMHRA (Medicines and Healthcare products Regulatory Agency)
- SpainAEMPS (Agencia Española de Medicamentos y Productos Sanitarios)
- ArgentinaANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)
- GermanyBfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
- FranceANSM (Agence nationale de sécurité du médicament et des produits de santé)
- ItalyAIFA (Agenzia Italiana del Farmaco)
- BrazilANVISA (Agência Nacional de Vigilância Sanitária)
- CanadaHealth Canada
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.